RxDoctor Payments Data

John Williams, MD

Endocrinology, Diabetes & Metabolism · Knoxville, TNNPI 1982605598

Payments from drug & device makers

$3,435in general payments, 2019–2025

Across 90 payments — averaging $38.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$2K
  • Dexcom, Inc.$442
  • Abbott$438
  • Amgen$228
  • Novartis$188
  • Asensus Surgical, Inc.$160
  • plus $428 from 12 others

What the payments were for

  • Speaking & faculty fees$1,55045%
  • Food & beverage$1,88555%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,435 in reported general payments places this provider in the 45th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

See all endocrinology, diabetes & metabolism providers in Tennessee

Medicare billing

Part B allowed, 2024
$154,930
Medicare patients
332
Services billed
8,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$157,996
ForteoTeriparatide27$115,272
MounjaroTirzepatide35$54,957
JardianceEmpagliflozin32$42,470
Tresiba Flextouch U-200Insulin Degludec11$29,785
Tresiba Flextouch U-100Insulin Degludec40$25,172
TrulicityDulaglutide14$22,714
Fiasp FlextouchInsulin Aspart (Niacinamide)17$17,052
SynthroidLevothyroxine Sodium198$16,509
FarxigaDapagliflozin Propanediol12$12,098
NovologInsulin Aspart24$9,773
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$8,734
Novolog FlexpenInsulin Aspart22$8,251
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$6,523
Testosterone38$6,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$50$167,769100 claims
Boehringer IngelheimJardiance$14$42,47032 claims
AbbVieSynthroid, Armour Thyroid$42$19,835232 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$5,148663 claims
PfizerLevoxyl$29$2,22444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

Other endocrinology, diabetes & metabolism in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →